Bioinformatic analysis reveals prognostic value and immunotherapy potential of Siglec-15 in laryngeal squamous cell carcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Siglec-15 (Sialic acid-binding immunoglobulin-like lectin 15) is upregulated in laryngeal squamous cell carcinoma (LSCC), predicting poor prognosis. Targeting Siglec-15 may improve immunotherapy response in LSCC patients.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Laryngeal squamous cell carcinoma (LSCC) presents a poor prognosis, with limited understanding of Siglec-15 (Sialic acid-binding immunoglobulin-like lectin 15) expression and clinical relevance.
- Investigating Siglec-15 is crucial for advancing immune-related research in LSCC.
Purpose Of The Study
- To determine the expression pattern and prognostic significance of Siglec-15 in LSCC.
- To explore the immune features modulated by Siglec-15 in LSCC using bioinformatics.
- To assess the impact of Siglec-15 on LSCC cell proliferation and invasion.
Main Methods
- Utilized TCGA-HNSC and GEO datasets (GSE27020, GSE25727) for gene expression and clinical data analysis.
- Employed immunohistochemistry, immunofluorescence, and qRT-PCR to analyze Siglec-15 expression in LSCC tissues and its correlation with prognosis and CD8+ T cell infiltration.
- Investigated Siglec-15's role in cell proliferation and invasion using human laryngeal cancer cell lines (LCC).
Main Results
- Siglec-15 was found to be upregulated in LSCC tissues.
- High Siglec-15 expression correlated with poorer overall survival (OS) in LSCC patients.
- Siglec-15 was identified as an independent predictor of poor prognosis and associated with an immunosuppressive tumor microenvironment, potentially limiting immunotherapy response.
- In vitro studies demonstrated that Siglec-15 enhances LSCC cell proliferation and invasion.
Conclusions
- Siglec-15 serves as a potential prognostic biomarker for LSCC.
- Siglec-15 represents a promising therapeutic target for enhancing LSCC immunotherapy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
